Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Study sponsor: Puma Biotechnology, Inc. · PBYI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-01-02Actual
Enrollment · participants582Actual
Source updated2024-03-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.